Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men

NCT00097825 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT00097825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00097825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2004
Completion date
August 31, 2007
Enrollment
288
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis